FDA
-
-
-
-
-
-
-
Quince Therapeutics Inc. (QNCX) PT Lowered to $8 at Citizens JMP
-
-
-
-
-
-
-
Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities
-
-
-
-
-
-
-
Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia
-
-
-
-
-
-
-
Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)
-
-
-
-
-
-
-
Quince Therapeutics (QNCX) Appoints Rajiv Patni to its Board
-
-
-
-
-
-
-
Quince Therapeutics Provides Pipeline Update and Business Outlook for 2023
-
-
-
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

